Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Sell Sage Group (SGE) by Canaccord Genuity
- Buy Michelmersh Brick Holdings (MBH) by Canaccord Genuity
- Buy B&M European Value Retail S.A. (DI) (BME) by Canaccord Genuity
- Neutral Anglo American (AAL) by JP Morgan
- Underweight Antofagasta (ANTO) by JP Morgan
- Overweight Fresnillo (FRES) by JP Morgan
- Overweight Hochschild Mining (HOC) by JP Morgan
- Outperform Breedon Group (BREE) by RBC Capital
- Buy LBG Media (LBG) by Shore Capital
- Buy DFS Furniture (DFS) by Jefferies
- Buy Balfour Beatty (BBY) by Deutsche Bank
- Buy Helios Underwriting (HUW) by Deutsche Bank
- Buy Jet2 (JET2) by Deutsche Bank
- Hold Sage Group (SGE) by Deutsche Bank
- Buy SSE (SSE) by HSBC
- Hold WPP (WPP) by HSBC
- Buy Flutter Entertainment (DI) (FLTR) by Goldman Sachs
- Buy Sage Group (SGE) by Citi
- Buy B&M European Value Retail S.A. (DI) (BME) by Citi
- Buy Clarkson (CKN) by Berenberg
Immupharma (IMM) Share Price
Health Care Sector
NOTE: This is based on 7 open tips for Immupharma (IMM)
| Latest Bid : 1.55p | Latest Ask : 1.60p |
| High Today : 1.69p | Low Today : 1.60p |
| This Years High : 2.61p | This Years Low : 0.85p |
| Volume : 454,326 | MKT Cap : £6.66M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Immupharma (IMM) Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.Immupharma (IMM) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Northland Capital | Premium Only | 2018-04-17 16:35:00 17/04/2018 | -60.41% |
| Risky Buy | Paul Summers | Premium Only | 2018-03-01 09:50:00 01/03/2018 | -92.31% |
| Buy | FinnCap | Premium Only | 2017-12-21 11:30:00 21/12/2017 | -91.87% |
| Buy | FinnCap | Premium Only | 2017-12-12 08:00:00 12/12/2017 | -93.10% |
| Buy | Harvey Jones | Premium Only | 2017-10-09 15:30:00 09/10/2017 | -86.07% |
Immupharma (IMM) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 1.55p | Latest Ask : 1.60p |
| High Today : 1.69p | Low Today : 1.60p |
| This Years High : 2.61p | This Years Low : 0.85p |
| Volume : 454,326 | MKT Cap : £6.66M |
Immupharma Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Immupharma Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Buy | Northland Capital | Premium Only | 2018-04-17 16:35:00 17/04/2018 | -60.41% |
| Risky Buy | Paul Summers | Premium Only | 2018-03-01 09:50:00 01/03/2018 | -92.31% |
| Buy | FinnCap | Premium Only | 2017-12-21 11:30:00 21/12/2017 | -91.87% |
| Buy | FinnCap | Premium Only | 2017-12-12 08:00:00 12/12/2017 | -93.10% |
| Buy | Harvey Jones | Premium Only | 2017-10-09 15:30:00 09/10/2017 | -86.07% |